Navigation Links
MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:7/31/2012

aws of any such state or other jurisdiction.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. 

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to our expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not we will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that we will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, MAP Pharmaceuticals and our business can be found under the heading "Risk Factors" in our most recent Form 10-Q filed with the SEC, in other filings that we periodically make with the SEC, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on the date hereof. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events a
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
3. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
4. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
7. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
8. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
9. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
10. WuXi PharmaTech Announces Third-Quarter 2011 Results
11. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... A new anti-sliding adhesive developed by engineers at the University ... to mimic the remarkable gecko toe hairs that allow the ... The researchers say that such an adhesive could one day ... up walls. , Taking a cue from the millions of ...
... to $0.72 on 19.8% Revenue Growth -, PRINCETON, ... earnings for its fourth quarter ended December 31, 2007,of ... both periods include,a $0.06 per share gain from the ... sale, earnings were $0.72 per diluted share in the,fourth ...
... 30 John Wagner, M.D., recognized as,a leader in ... joined,the team at CORD:USE Cord Blood Bank. Dr. Wagner,s ... biology will provide a,significant contribution to CORD:USE., "We,re ... of our,distinguished team," says Edward Guindi, M.D., President and ...
Cached Biology Technology:New adhesive mimics gecko toe hairs 2New adhesive mimics gecko toe hairs 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 2Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 3Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 4Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 5Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 6Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 7Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 8Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 9Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 10Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20% 11CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 3
(Date:8/21/2014)... New feeding tube connectors, designed by an international standards ... safety. , According to an invited review published in ... ( NCP ), the official journal of the ... new connectors will greatly reduce the occurrence of misconnection ... , Small-bore connectors, which are used to join medical ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2
... ,chocolate, cysts for the brown liquid they contain, can ... which can cause ongoing pain and complications. A study ... effective remedy the oral contraceptive pill (OCP). ... from Auckland, New Zealand, highlight a trial published in ...
... L. Rimoin, MD, PhD, FACMG of Cedars-Sinai Medical Center ... Medical Genetics Foundation (ACMGF) second annual Lifetime Achievement Award ... was recognized for his decades of contributions to genetic ... disorders of connective tissue, and for helping to organize ...
... urine drives crayfish into an aggressive sexual frenzy. Researchers ... suggest that a urine-mediated combination of aggressive and ... to mate. Fiona Berry and Thomas Breithaupt from ... urine-based chemical signaling on sexually active crayfish. Breithaupt said, ...
Cached Biology News:Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 2Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award 3
... Galaxy LIMS, Sophisticated Bioinformatics , Proprietary primer ... offer individual sample sequencing of PCR products, ... or double strand publication quality. Primer ... interest is 1.3 to 7 kilobytes long. ...
Shotgun library construction and high-throughput DNA sequencing of microbial genomes, BACs, adenoviruses, phosmids and cosmids. LIMS tracking utilizing Geospiza's Finch system....
...
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
Biology Products: